【ChiCTR2600125772】Fractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot Study
ChiCTR2600125772
尚未开始
/
/
/
2026-05-31
/
/
Acne
Fractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot Study
Fractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot StudyFractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot Study
41002
To compare the efficacy of fractional RF microneedling combined with low-dose isotretinoin versus standard-dose isotretinoin monotherapy. To evaluate the safety of RF microneedling during concurrent isotretinoin therapy. To assess the impact of body mass index on treatment response. To examine the influence of lifestyle-related confounders on clinical outcomes
随机平行对照
其它
Randomization was done by a computer-generated permuted block randomization method (block size = 6).The research team used sealed envelopes, which they had prepared in sequential order, to conduct 1:1 patient randomization between the two treatment groups
None
None
/
20
/
2026-05-30
2027-05-01
/
The study included patients aged 18 to 33 years with moderate-to-severe acne vulgaris of the face, as defined by an Investigator Global Assessment (IGA) score of 3 or 4. All patients had failed or were unsuitable for conventional topical therapy alone. The study included patients aged 18 to 33 years with moderate-to-severe acne vulgaris of the face, as defined by an Investigator Global Assessment (IGA) score of 3 or 4. All patients had failed or were unsuitable for conventional topical therapy alone.;
请登录查看Patients were excluded from the study when they met any of these criteria: 1.They had used isotretinoin during the last 12 months; 2.They had documented hypersensitivity to retinoids; 3.They were currently suffering from active hepatic or renal or metabolic diseases; 4.Females were pregnant or they refused to follow birth control rules; 5.They had an existing skin infection at the sites where RF treatment was scheduled; 6.They had received RF microneedling treatment within the 6 months before their enrollment date.;
请登录查看University of Mosul
41002
University of Mosul的其他临床试验
- Fractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot Study
- Effectiveness and Safety of Topical Tofacitinib 2% Ointment versus Metronidazole 0.75% Cream in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial.
- Management of acne scars by sequential combination of micro-needle radiofrequency followed by fractional CO2 laser versus each therapy alone
University of Mosul的其他临床试验
- Fractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot Study
- Effectiveness and Safety of Topical Tofacitinib 2% Ointment versus Metronidazole 0.75% Cream in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial.
- Management of acne scars by sequential combination of micro-needle radiofrequency followed by fractional CO2 laser versus each therapy alone
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29
